Wednesday, October 30, 2019

The Gut-Brain Axis: A New Frontier for Understanding Mental Illness



     In recent years the prevalence of mental illness continues to rapidly increase, affecting nearly one in five adults in the United States (1). These disorders present as an especially challenging medical burden with lower rates of treatment and recovery than any other disease, as the complexity of human psychiatry is still poorly understood.

     Psychiatric disorders are generally thought of as originating solely within the brain, but recent studies are shifting the paradigm.  With the increasing awareness that  the human being is a superorganism, it has become apparent that  the microbiota-gut-brain axis likely plays  a major role in mental health.




Figure 1.  The increasing medical burden of mental and neurological disorders. (A,B): Disability-adjusted life years (DALYs) of disorders. (C,D): DALYs for different respective diseases in 1990, 2006, and 2016 (2).


     The human gut is the largest endocrine organ of the body with 90-95% of its total cell count shockingly consisting of microorganisms.  It also possesses its own nervous system. The gut microbiota develops simultaneously with the brain, impacting both its structure, i.e., rate of myelination and synaptic connectivity and its function by altering  cognition (3). The developmental mirroring of the gut and brain intuitively suggests a very intimate physiological dichotomy between the two. Beyond development, the microbiome of the gut has been demonstrated to play a significant role in one’s cognition and behavior, although this role is still poorly understood and usually ignored.
Some functions that the microbiome have been shown to regulate are perception and response to pain  (4,5), cognitive abilities (i.e., learning and memory) (6,7) and of particular interest, mood and emotion (4,5).


Figure 2. Developmental patterns illustrating the similarity and intimacy of the gut-brain axis (3)

     A recent study that exemplifies this dichotomy showed that changes in the fecal metabolome, which are indicative of an altered gut microbiome, were significantly associated with depressive-like phenotypes in rats subjected to chronic unpredictable mild stress (8). More specifically, changes in the fecal abundance of multiple essential amino acids were correlated with changes in the plasma metabolomes of the rats that exhibited depressive-like behavior in response to stress. Depressive disorders have commonly been correlated with disturbed amino acid synthesis and metabolism, which is the paramount duty of the brain attributed to the gut microbiome, and the key mechanism for mediating the communication between the two. These results suggest that the gut microbiota, and more specifically its associated metabolites, may play a crucial role in the pathogenesis of depressive-like mammalian behaviors.



     Another recent study has investigated the influence of the gut microbiome on neural reward pathways in attention-deficit/hyperactivity disorder (ADHD) (9). ADHD is a highly prevalent mental disorder characterized by chronic patterns of inattention and impulsivity that can impede normal cognitive function or development. Though ADHD is poorly understood, it is thought to potentially be associated with lower levels of the neurotransmitter dopamine in the basal ganglia of the brain, which contributes to the brain’s “reward system.” Using 16S rRNA gene sequencing and fMRI, gut bacterial identities and neural responses to reward anticipation were evaluated in 28 human subjects who were either diagnosed with ADHD or were healthy controls. The resulting data revealed that the genus Bifidobacterium was present at significantly higher levels in ADHD patients than the controls and correlated with decreased ventral striatal fMRI responses during reward anticipation. This bacterium is crucially involved in the synthesis of phenylalanine – an essential amino acid, and a precursor molecule to dopamine. Although the mechanism of ADHD pathology associated with this bacterium isn’t clear, the disturbance in its normal levels of gut colonization were nevertheless correlated with clinical signs of mental disorder.
 
Figure 3. Potential pathways of basic microbiome influence on brain function (9).

     To conclude, the relationship between the gut and brain plays a unique and inseparable role to our mental health.  Further understanding of the gut-brain axis could reveal novel pharmacological interventions and therapies as a solution to a multitude of mental illnesses.  With regards to our limited current understanding, some theoretical solutions that could be imagined are: individualized probiotic supplements to properly recolonize patient microflora; immunotherapies to target and control unwanted overabundance of specific bacterial taxa; exogenous supplementation with the specific enzymatic byproducts of bacterial metabolism; or even genetic modification via technologies such as CRISPR of human host cells that are the environmental framework supporting these bacteria and their activity.

By:  Titus Lemaster, Master's of Medical Sciences Student, University of Kentucky

References:

1. “Mental Illness.” (2017). National Institute of Mental Health, U.S. Department of Health and Human Services, https://www.nimh.nih.gov/health/statistics/mental-illness.shtml.

2. GBD 2015 DALYs and HALE Collaborators. “Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.” Lancet (London, England) vol. 388,10053 (2016): 1603-1658. doi:10.1016/S0140-6736(16)31460-X

3. Liang, Shan et al. “Gut-Brain Psychology: Rethinking Psychology From the Microbiota-Gut-Brain Axis.” Frontiers in integrative neuroscience vol. 12 33. 11 Sep. 2018, doi:10.3389/fnint.2018.00033

4. Luczynski P., McVey Neufeld K. A., Oriach C. S., Clarke G., Dinan T. G., Cryan J. F. (2016). Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. Int. J. Neuropsychopharmacol. 19:pyw020. 10.1093/ijnp/pyw020
  
5. Vuong H. E., Yano J. M., Fung T. C., Hsiao E. Y. (2017). The microbiome and host behavior. Ann. Rev. Neurosci. 40 21–49. 10.1146/annurev-neuro-072116-031347 

6. Gareau M. G. (2016). Cognitive function and the microbiome. Int. Rev. Neurobiol. 131 227–246. 10.1016/bs.irn.2016.08.001 

7. Manderino L., Carroll I., Azcarate-Peril M. A., Rochette A., Heinberg L., Peat C., et al. (2017). Preliminary evidence for an association between the composition of the gut microbiome and cognitive function in neurologically healthy older adults. J. Int. Neuropsychol. Soc. 23 700–705. 10.1017/S1355617717000492

8. Jianguo, Li et al. “Altered gut metabolome contributes to depression-like behaviors in rats exposed to chronic unpredictable mild stress.” Translational psychiatry vol. 9,1 40. 29 Jan. 2019, doi:10.1038/s41398-019-0391-z 
                         
9. Aarts, Esther et al. “Gut microbiome in ADHD and its relation to neural reward anticipation.” PloS one vol. 12,9 e0183509. 1 Sep. 2017, doi:10.1371/journal.pone.0183509



















Monday, October 28, 2019

Opioid Sparing Sedation and Analgesia

Kentucky is one of the states most heavily affected by the opioid epidemic. The National Institute on Drug Abuse (NIDA) reported, “In 2017, there were 1,160 reported opioid-involved deaths in Kentucky—a rate of 27.9 deaths per 100,000 persons, compared to the average national rate of 14.6 deaths per 100,000 persons.”1 While most of these deaths are related to synthetic opioids, prescription opioid related deaths have remained at high, steady rate over the years.1  
NIDA reported, “Kentucky is among the top 10 states with the highest prescribing rates.1 In 2017, Kentucky providers wrote 86.8 opioid prescriptions for every 100 persons compared to the average U.S. rate of 58.7 prescriptions.”1 While the rate of opioid prescriptions being written has decreased since 2011, the number of deaths is still increasing as reported by NIDA.1 

Let’s start with what an opioid is... 

     Opioids are a class of drugs that are produced by the opium poppy plant. There are many different drugs that are in the opioid class, but they all have a sedative and analgesic effect. While opioids are a potent “pain-killer” and sedative, they can also produce a relaxed conscious state. This feeling of relaxation is enticing to individuals which can lead to addiction.2  
     Morphine is a commonly used opioid, especially in the hospital setting. Morphine is the opioid to which other opioids are compared. Morphine works on the kappa, delta, and mu opioid receptors.3 The “pain-killing” effect that is produced by morphine binding to mu opioid receptor which is located in the central and peripheral nervous systems.3 The mu opioid receptor is also expressed on respiratory stimulating neurons in the brain stem; this means the sedative effects of morphine can cause respiratory depression that can lead to death.4 

      So, you may be asking what led to this opioid epidemic of death and addiction? While there are many factors, one of the most commonly discussed in the healthcare community is the Pain as the 5th Vital Sign campaign that started in 2001 by the Joint Commission.5 This campaign was to help healthcare professionals assess and treat pain better. Although, in 2016, the Joint Commission formed a panel to review their guidelines and previous recommendations.6 They reported that while it is important to assess and treat pain, “an inter-professional team approach to implementing multi-dimensional pain assessment tools in clinical practice is therefore needed.”6  
     Given the life-threatening, additive properties of opioids, health care providers are moving towards “opioid sparing analgesia” and “multimodal analgesia.” The American Association of Nurse Anesthetist and the American Society of Anesthesiologists recommend to treat pain with opioids and non-opioids if appropriate; meaning, some patients may not even require opioids for their pain control. They state, “using opioids alone may adversely affect the patients postoperative recovery...combining opioids with non-opioids creates a synergy that magnifies the analgesic effect of each.”7  
     Non-opioid medications that can be used alone or in conjunction with opioids for analgesia are non-steroidal anti-inflammatories such as ibuprofen and ketorolac, and acetaminophen. Ketorolac and acetaminophen are available in the intravenous form which makes it easy to give in operative stages or if a patient cannot eat.7 Non-opioid drugs that can be used for sedation purposes that are intravenous ketamine and dexmedetomidine. While every drug has side effects, none of the previously mentioned drugs lead to respiratory depression if properly administered.7 
     A recent study showed that patient satisfaction was just as high if not better when patients were given non-opioids such as ibuprofen and acetaminophen for their post operative period.8 The participants reported little to no opioid use and still were able to complete their activities of daily living which shows that non-opioid analgesia can and does work for most individuals.8   
     More invasive yet reportedly helpful forms of pain control for patients using the opioid sparing techniques are radio frequency ablation of the involved nerve/s and nerve blocks that involve injecting a numbing agent into the affected area.9 Patients also report positive results from transcutaneous electrical nerve stimulation that interrupts the nerve signals, and spinal cord stimulation that can help with lower back pain.9 Other interventions include: acupuncture, physical therapy, and more studies are being done on the use of cannabidiol and stem cell injections.9 




References 
  1. 1.  Kentucky Opioid Summary. (2019). Retrieved 14 October 2019, from https://www.drugabuse.gov/opioid-summaries-by-state/kentucky-opioid-summary 
  1. 2.  Butanis, B. (2019). What Are Opioids?. Retrieved 14 October 2019, from https://www.hopkinsmedicine.org/opioids/what-are-opioids.html 
  1. 3.  Pathan, H., & Williams, J. (2012). Basic opioid pharmacology: an update. Retrieved 14 October 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590096/ 
  1. 4.  Boom, M., Niesters, M., Sarton, E., Aarts, L., Smith, T., & Dahan, A. (2012). Non-analgesic effects of opioids: opioid-induced respiratory depression. - PubMed - NCBI. Retrieved 14 October 2019, from https://www.ncbi.nlm.nih.gov/pubmed/22747535 
  1. 5.  Baker, D. (2017). The Joint Commission's Pain Standards: Origins and Evolution. 
  2. Retrieved 14 October 2019, from https://www.jointcommission.org/assets/1/6/Pain_Std_History_Web_Version_05122017.pdf 
  1. 6.  Scher, C., Meador, L., Van Cleave, J., & Reid, M. (2018). Moving Beyond Pain as the Fifth Vital Sign and Patient Satisfaction Scores to Improve Pain Care in the 21st Century. Retrieved 14 October 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878703/ 
  1. 7.  Vo, B., Clayton, E., & Stolyarskaya, J. (2018). Opioid and non-opioid analgesia during surgery - American Nurse Today. Retrieved 14 October 2019, from https://www.americannursetoday.com/opioid-non-opioid-analgesia-surgery/ 
  1. 8.  Hallway, A., Vu, J., Palazzolo, W., Waljee, J., Brummett, C., Englesbe, M., & Howard, R. (2019). Patient Satisfaction and Pain Control Using an Opioid-Sparing Postoperative Pathway. Retrieved 14 October 2019, from https://www.ncbi.nlm.nih.gov/pubmed/31154092 
  1. 9.  Non-Opioid Treatment for Chronic Pain - When Seconds Count. Retrieved 14 October 2019, from https://www.asahq.org/whensecondscount/pain-management/non-opioid-treatment/